Literature DB >> 11432688

Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat.

L C Vargas1, L C Schenberg.   

Abstract

RATIONALE: The defensive responses induced by electrical stimulation of dorsal periaqueductal grey (DPAG) of the rat have been proposed as a model of panic attacks in humans.
OBJECTIVE: The present experiments were carried out to evaluate the long-term effects of clinically effective panicolytics on these responses.
METHODS: Rats that had electrodes implanted into the DPAG were treated for 21 days with clomipramine (CLM; 5, 10 and 20 mg/kg), fluoxetine (FLX; 1 and 5 mg/kg) or saline. Long-term effects were assessed prior to the treatment to avoid acute drug effects. Threshold logistic functions of defensive responses were compared by likelihood ratio coincidence tests.
RESULTS: CLM attenuated DPAG-evoked defensive behaviours at a time-course similar to that observed in panic therapy. Administration of 10 mg/kg CLM for 21 days produced significant increases in the thresholds of immobility (24%), running (49%) and jumping (45%). Splitting of running into single responses disclosed selective threshold increases of galloping (75%) and trotting (138%) with 5 and 10 mg/kg, respectively. Thresholds of micturition were markedly increased (87%) by 5 mg/kg CLM. In turn, FLX (1 mg/kg) virtually abolished the galloping response. No threshold changes were observed following the long-term administration of the higher dose of either CLM or FLX. Saline-treated rats had a significant increase (35%) in galloping thresholds only.
CONCLUSIONS: The present data partially validate the DPAG-evoked defence reaction of the rat as a model of panic attacks in humans. Attenuation of galloping by lower doses of FLX and CLM also suggests the prominent modulation of this response by serotonin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432688     DOI: 10.1007/s002130100698

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

Review 1.  The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.

Authors:  Evan D Paul; Philip L Johnson; Anantha Shekhar; Christopher A Lowry
Journal:  Neurosci Biobehav Rev       Date:  2014-03-21       Impact factor: 8.989

2.  The amygdala differentially regulates defensive behaviors evoked by CO2.

Authors:  R J Taugher; B J Dlouhy; C J Kreple; A Ghobbeh; M M Conlon; Y Wang; J A Wemmie
Journal:  Behav Brain Res       Date:  2019-09-16       Impact factor: 3.332

3.  Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray.

Authors:  Valquíria Camin de Bortoli; Regina Lúcia Nogueira; Hélio Zangrossi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-29       Impact factor: 4.530

4.  PET imaging on neurofunctional changes after optogenetic stimulation in a rat model of panic disorder.

Authors:  Xiao He; Chentao Jin; Mindi Ma; Rui Zhou; Shuang Wu; Haoying Huang; Yuting Li; Qiaozhen Chen; Mingrong Zhang; Hong Zhang; Mei Tian
Journal:  Front Med       Date:  2019-07-18       Impact factor: 4.592

5.  Benzodiazepine receptor and serotonin 2A receptor modulate the aversive-like effects of nitric oxide in the dorsolateral periaqueductal gray of rats.

Authors:  Fabrício Araújo Moreira; Francisco Silveira Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2004-07-22       Impact factor: 4.530

6.  Ionotropic glutamate-receptor antagonists inhibit the aversive effects of nitric oxide donor injected into the dorsolateral periaqueductal gray of rats.

Authors:  Fabrício Araújo Moreira; Moriana Ludmilla Molchanov; Francisco Silveira Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

7.  Efficacy of chronic antidepressant treatments in a new model of extreme anxiety in rats.

Authors:  Hervé Javelot; Luisa Weiner; Roxane Terramorsi; Catherine Rougeot; Robert Lalonde; Michaël Messaoudi
Journal:  Depress Res Treat       Date:  2011-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.